Navigation Links
SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
Date:1/8/2008

Organization expands SRA footprint in human health services around the

world

FAIRFAX, Va., Jan. 8 /PRNewswire-FirstCall/ -- As part of its overall expansion in new markets, SRA International, Inc. (NYSE: SRX) today announced the appointment of Timothy J. Atkin as Senior Vice President and Mike Toner as Vice President and Chief Financial Officer (CFO) of its new Global Health Sector (GHS) organization. GHS was formed in October 2007 to expand SRA's footprint in the health services marketplace following its acquisition of Constella Group, LLC, a global professional health services company.

"Global Health is an important business area for SRA . and one with great potential for growth," said SRA President & CEO Stanton Sloane.

SRA's GHS serves public, private, and non-profit clients in more than 40 countries around the world, including the U.S. Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA); both U.S. and United Kingdom international development agencies; Department of Defense (DoD) health, pharmaceutical, and biotechnology companies; and such foundations as the Bill & Melinda Gates Foundation.

Atkin, previously SRA Senior Vice President, Civil Sector, is responsible for the day-to-day management and operations of the GHS organization, overseeing the execution of all programs and the growth and expansion of the unit. In his previous role, Atkin was responsible for developing and managing all of SRA's civil government business, which included serving such clients as HHS, the Department of the Interior, the Department of Labor, Veterans Affairs, the Environmental Protection Agency (EPA), and the U.S. Agency for International Development (USAID).

Atkin is a former member of the Senior Executive Service at the U.S. Department of Labor, served twice on the White House staff at the National Security Council and at the Office of National Drug Control Policy, and in 2002 was named by Federal Computer Week to its list of the top 100 individuals who made the greatest impact in federal information technology (IT) during 2001. Atkin will report to Sloane.

"Tim brings the right mix of industry and government experience to the role," said Sloane. "He ran SRA's legacy health and international development business and knows the synergies between the solutions and services SRA has offered and the new ones added with the acquisition of Constella. Tim is a great fit for this new leadership role."

Toner has served as acting CFO of GHS and now assumes the Vice President and CFO position permanently. Toner joined SRA in July 2005 as part of the Galaxy Scientific Corporation acquisition. He has held a number of key financial posts, including director of Financial Controls and Processes and Defense Sector controller and led the acquisition integration of RABA Technologies in 2007. He is also a Certified Public Accountant. Toner will report to SRA CFO and Executive Vice President of Operations Stephen Hughes.

"Tim and Mike are a great fit for GHS," said Sloane. "We intend to invest in our global health business moving forward and have high expectations for this organization."

About SRA International, Inc.

SRA is a leading provider of technology and strategic consulting services and solutions -- including systems design, development, and integration; and outsourcing and managed services -- to clients in national security, civil government, and health care and public health markets. The Company also delivers business solutions for contingency and disaster response planning, information assurance, business intelligence, environmental strategies, enterprise architecture, infrastructure management, and wireless integration.

FORTUNE(R) magazine has chosen SRA as one of the "100 Best Companies to Work For" for eight consecutive years. The Company's 6,300 employees serve clients from its headquarters in Fairfax, Virginia, and offices around the world. For additional information on SRA, please visit http://www.sra.com.

Any statements in this press release about future expectations, plans, and prospects for SRA, including statements containing the words "estimates," "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. In addition, the forward-looking statements included in this press release represent our views as of January 8, 2008. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to January 8, 2008.


'/>"/>
SOURCE SRA International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
4. Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board
5. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
6. Genome Technology Magazine Names Top Young Investigators of 2007
7. STEM CELLS Journal Names Co-Editors
8. Phlo Affiliate Names Director Of Marketing
9. Immunosyn Corporation Names G. David Criner as CFO
10. Navitas Names Dr. Dean Gesme as Medical Director
11. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
Breaking Biology News(10 mins):